Get Live Data

The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE
Roundtable Discussion; The Future of Mineral Sands
Roundtable Discussion; The Future of Mineral SandsView Video

Latest Share Chat

  2. Share Prices
  3. Allergy Thera. Share Price
  4. Allergy Thera. Share News
  5. IN BRIEF: Allergy Therapeutics Secures VLP Technology Platform

Pin to quick picksAllergy Thera. Share News (AGY)

Allergy Thera. Information

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.875
Bid: 2.75
Ask: 3.00
Change: 0.00 (0.00%)
Spread: 0.25 (9.091%)
Open: 2.875
High: 3.00
Low: 2.875
Prev. Close: 2.875
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Allergy Therapeutics Secures VLP Technology Platform

Fri, 04th Sep 2020 19:39

Allergy Therapeutics PLC - Sussex-based biotechnology firm - Secures virus-like particle technology platform to increase vaccine pipeline through licensing agreement with Saiba AG and DeepVax GmbH.

The company will use their platform to develop and commercialise vaccine targeting cancer tumours, atopic dermatitis and psorasis. Already Allergy has an agreement to develop a new VLP vaccine immunotherapy treatment for peanut allergy sufferers.

Current stock price: 20.50 pence

Year-to-date change: up 100%

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
30 Nov 2015 09:25

Allergy Therapeutics Completes Patient Enrolment For Birch Study

Read more
17 Nov 2015 14:36

Allergy Therapeutics raises £12m to develop peanut and dust mite treatments

(ShareCast News) - Shares in Allergy Therapeutics fell as, despite a strong trading update, the company launched a £12m discounted fundraising to speed development of treatments for peanut allergy and house dust mites allergies. The AIM-listed company completes the institutional placing by mid-after

Read more
17 Nov 2015 13:03

UPDATE: Allergy Therapeutics Raises GBP11.5 Million To Fund Growth (ALLISS)

Read more
17 Nov 2015 10:14

Allergy Therapeutics To Raise GBP12 Million To Fund Growth (ALLISS)

Read more
16 Nov 2015 16:37

AGM, EGM Calendar - Week Ahead

Read more
4 Nov 2015 10:43

Allergy Therapeutics To Present Adjuvant Data At Spain Conference

Read more
13 Oct 2015 08:43

BROKER RATINGS SUMMARY: Citi Cuts AB Foods As UBS Raises Smiths Group

Read more
21 Sep 2015 08:11

Allergy Therapeutics Says Outlook "Very Positive" As Profit Falls

Read more
14 Sep 2015 14:58

Earnings, Trading Statements Calendar - Week Ahead

Read more
1 Sep 2015 08:35

Allergy Therapeutics Enrols First Patient For Birch Drug Study

Read more
10 Aug 2015 07:23

Allergy Therapeutics Says Paper Published In World Allergy Journal

Read more
27 Jul 2015 16:58

Allergy Technologies' chief executive buys 50,000 shares

(ShareCast News) - The chief executive of Allergy Therapeutics bought new shares in the company few days after releasing a positive trading update. Manuel Llobet purchased 50,000 shares for an individual price of 24.45p, spending a total of £12,225. After the transaction, Llobet holds 3.175m shares

Read more
27 Jul 2015 16:24

DIRECTOR DEALINGS SUMMARY: New MySale Chairman Buys 60,000 Shares

Read more
27 Jul 2015 11:37

DIRECTOR DEALINGS: Allergy Therapeutics CEO Buys 50,000 Shares

Read more
23 Jul 2015 08:38

Allergy Therapeutics Expects Revenue Growth Despite Euro Weakness

Read more
6789101112131415

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.